What I found particularly interesting was that he has been involved in one way or another with the research / trials of every HIV antiviral therapy currently available. More recently, despite being met with much controversy, Professor Cooper was instrumental in the driving of Truvada® for PrEP to be PBS listed. As a pharmacist, I see firsthand the positive impact that the PBS listing of previously restricted access and/or high cost medications can have, not only on patients’ direct health, but also on their psycho-social well being as well. It is professionally rewarding being able to see patients access medications that were previously unavailable or too costly, so I thank you Professor Cooper.
Professor Cooper has unequivocally made a profound and long lasting impact on HIV research and treatment globally. It is evident that his legacy is an inspiration to all promoting research, treatment, advocacy, collaboration, strength and courage. I could not think of a more fitting opening for what looks like an invaluable and rewarding conference.
